Suppr超能文献

阿尔茨海默病中的淡漠:有任何有效治疗方法吗?

Apathy in Alzheimer's disease: any effective treatment?

作者信息

Rea Raffaele, Carotenuto Anna, Fasanaro Angiola M, Traini Enea, Amenta Francesco

机构信息

Centro di Ricerche Cliniche, Telemedicina e Telefarmacia, Università di Camerino, 62032 Camerino, Italy ; Unità Complessa Neurologia, Azienda Ospedaliera di Rilievo Nazionale A. Cardarelli, 80131 Naples, Italy.

Unità Complessa Neurologia, Azienda Ospedaliera di Rilievo Nazionale A. Cardarelli, 80131 Naples, Italy.

出版信息

ScientificWorldJournal. 2014 Feb 2;2014:421385. doi: 10.1155/2014/421385. eCollection 2014.

Abstract

OBJECTIVE

This review has evaluated the effectiveness of pharmacological treatment of apathy in patients with Alzheimer's disease (AD).

METHODS

A systematic literature search was conducted on published clinical trials assessing the effects of pharmacological treatment on apathy in AD over the last 10 years.

RESULTS

Fourteen studies considered of good quality were included in the analysis (4 randomized controlled trials, 9 open-label studies, and 1 retrospective analysis). Cholinesterase inhibitors were investigated in 9 studies, monoaminergic compounds such as methylphenidate and modafinil in two trials and one trial, respectively, and Ginkgo biloba (EGb 761 extract) and citalopram in one study each. Cholinesterase inhibitors did not show statistical significant effect in 1 RCT study but were associated to improvement in 3 open-label studies. Methylphenidate elicited a small but significant activity accompanied by relevant side effects such as high blood pressure, cough, and osteoarticular pain. EGb 761 was well tolerated and countered apathy. Other treatments induced modest improvements or were ineffective.

CONCLUSIONS

Apathy treatment remains a challenge and there is no evident advantage of any specific pharmacotherapy tested so far. The development of controlled studies according to updated guidelines for the diagnosis of apathy in patients with AD is desirable.

摘要

目的

本综述评估了药物治疗对阿尔茨海默病(AD)患者淡漠症状的有效性。

方法

对过去10年发表的评估药物治疗对AD患者淡漠症状影响的临床试验进行了系统的文献检索。

结果

分析纳入了14项质量良好的研究(4项随机对照试验、9项开放标签研究和1项回顾性分析)。9项研究中研究了胆碱酯酶抑制剂,两项试验和一项试验中分别研究了单胺能化合物如哌甲酯和莫达非尼,各有一项研究分别研究了银杏叶提取物(EGb 761)和西酞普兰。胆碱酯酶抑制剂在1项随机对照试验研究中未显示出统计学显著效果,但在3项开放标签研究中与症状改善相关。哌甲酯产生了微小但显著的作用,伴有高血压、咳嗽和骨关节疼痛等相关副作用。EGb 761耐受性良好且可对抗淡漠症状。其他治疗产生了适度改善或无效。

结论

淡漠症状的治疗仍然是一项挑战,迄今为止所测试的任何特定药物治疗均无明显优势。根据AD患者淡漠症状诊断的更新指南开展对照研究是可取的。

相似文献

1
Apathy in Alzheimer's disease: any effective treatment?
ScientificWorldJournal. 2014 Feb 2;2014:421385. doi: 10.1155/2014/421385. eCollection 2014.
2
Pharmacological Therapy for Apathy in Alzheimer's Disease: A Systematic Review and Meta-Analysis.
Can J Neurol Sci. 2017 May;44(3):267-275. doi: 10.1017/cjn.2016.426. Epub 2017 Feb 2.
5
Methylphenidate and Other Pharmacologic Treatments for Apathy in Alzheimer's Disease.
J Clin Psychiatry. 2022 Feb 1;83(1):22f14398. doi: 10.4088/JCP.22f14398.
6
Pharmacological and Nonpharmacological Treatment for Apathy in Alzheimer Disease : A systematic review across modalities.
J Geriatr Psychiatry Neurol. 2017 Jan;30(1):26-49. doi: 10.1177/0891988716678684.
9
Evidence-based pharmacotherapy of Alzheimer's disease.
Int J Neuropsychopharmacol. 2004 Sep;7(3):351-69. doi: 10.1017/S1461145704004444. Epub 2004 Jul 1.
10
Galantamine for Alzheimer's disease.
Cochrane Database Syst Rev. 2001(4):CD001747. doi: 10.1002/14651858.CD001747.

引用本文的文献

1
GWAS links APOE to neuropsychiatric symptoms in mild cognitive impairment and dementia.
Alzheimers Dement. 2025 Jun;21(6):e70329. doi: 10.1002/alz.70329.
2
GWAS links to neuropsychiatric symptoms in mild cognitive impairment and dementia.
medRxiv. 2025 Feb 2:2025.01.31.25321498. doi: 10.1101/2025.01.31.25321498.
3
Understanding neuropsychiatric symptoms in Alzheimer's disease: challenges and advances in diagnosis and treatment.
Front Neurosci. 2023 Sep 5;17:1263771. doi: 10.3389/fnins.2023.1263771. eCollection 2023.
5
Apathy: Neurobiology, Assessment and Treatment.
Clin Psychopharmacol Neurosci. 2021 May 31;19(2):181-189. doi: 10.9758/cpn.2021.19.2.181.
8
Apathy in Alzheimer's disease.
Curr Opin Behav Sci. 2018 Aug;22:7-13. doi: 10.1016/j.cobeha.2017.12.007.
9
Peptide YY Causes Apathy-Like Behavior via the Dopamine D2 Receptor in Repeated Water-Immersed Mice.
Mol Neurobiol. 2018 Sep;55(9):7555-7566. doi: 10.1007/s12035-018-0931-1. Epub 2018 Feb 10.

本文引用的文献

3
REVIEW: Apathy diagnosis, assessment, and treatment in Alzheimer's disease.
CNS Neurosci Ther. 2010 Oct;16(5):263-71. doi: 10.1111/j.1755-5949.2009.00132.x.
4
Effects of rivastigmine on common symptomatology of Alzheimer's disease (EXPLORE).
Curr Med Res Opin. 2010 May;26(5):1149-60. doi: 10.1185/03007991003688888.
5
Methylphenidate for apathy and functional status in dementia of the Alzheimer type.
Am J Geriatr Psychiatry. 2010 Apr;18(4):371-4. doi: 10.1097/JGP.0b013e3181cabcf6.
6
Pharmacological treatment of apathy in neurodegenerative diseases: a systematic review.
Dement Geriatr Cogn Disord. 2009;28(1):13-22. doi: 10.1159/000228840. Epub 2009 Jul 17.
7
Effect of a serotonin reuptake inhibitor on irritability, apathy, and psychotic symptoms in patients with Alzheimer's disease.
J Clin Psychiatry. 2009 Jun;70(6):915-8. doi: 10.4088/JCP.08m04828. Epub 2009 May 5.
8
Proposed diagnostic criteria for apathy in Alzheimer's disease and other neuropsychiatric disorders.
Eur Psychiatry. 2009 Mar;24(2):98-104. doi: 10.1016/j.eurpsy.2008.09.001. Epub 2009 Feb 7.
10
Effectiveness and safety of donepezil in Hispanic patients with Alzheimer's disease: a 12-week open-label study.
J Natl Med Assoc. 2008 Nov;100(11):1350-8. doi: 10.1016/s0027-9684(15)31515-7.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验